

17 JULY 2025

PACIFIC EDGE OPENS \$5.0 MILLION SHARE PURCHASE PLAN

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge Limited (“Pacific Edge”, the “Company”) (NZX, ASX: PEB) today announces the opening of its Share Purchase Plan (“SPP”) to raise \$5.0 million.

This SPP is further to the announcement on 3 June 2025 in respect of Pacific Edge’s successful conditional placement (the “Placement”)¹ of \$16.1 million of new ordinary shares to certain investors — \$1.1 million more than originally sought — at a price of \$0.10 per share to support an aggregate capital raising of circa \$21.0 million. The Placement is conditional on shareholder approval, which is to be sought at the Annual Shareholders’ Meeting on 6 August 2025. The issue of shares under the SPP is conditional on the Placement becoming unconditional.

The SPP is open to “Eligible Shareholders”, who are all persons recorded on Pacific Edge’s share register at 7:00pm NZT on 11 July 2025 as being a holder of Pacific Edge shares and who have an address in New Zealand.

Eligible Shareholders are able to apply for up to a maximum of \$50,000 of new shares per shareholder at \$0.10 per share, the same price per share offered to investors that took part in the Placement. Pacific Edge can elect to accept oversubscriptions at its absolute discretion to ensure that it has sufficient flexibility to cater for demand from its retail shareholder base.²

The new shares to be issued under the SPP and Placement (subject to those offers becoming unconditional) are expected to be allotted on 13 August 2025 and will rank equally with existing Pacific Edge shares on issue on the allotment date. Pacific Edge envisages using the new capital to:

- Extend cash runway to support operations for over 12 months without Medicare coverage, and without reductions in its cost base, while pursuing re-coverage;
- Accelerate adoption of Triage in the US with its February 2025 inclusion in the American Urological Association (AUA) microhematuria guideline as a catalyst for sales, marketing and reimbursement;
- Continue generating clinical evidence in an AV, CV and CU³ framework for coverage, guidelines and medical policy for Triage Plus and Monitor Plus; and
- Invest in innovation and product development for In Vitro Diagnostic (IVD) kits to support entry into international markets in a decentralised deployment model.

¹ A separate Notice of Annual Shareholders’ Meeting is also being released to the NZX and ASX today detailing the resolutions to be put to shareholders including the resolution relating to the Placement.

² Pacific Edge also reserves the right to scale oversubscriptions under the SPP. If it does so, oversubscriptions will be scaled according only to the number of shares held by applicants under the SPP at 7.00pm NZT on 11 July 2025.

³ AV: Analytical Validity; CV: Clinical Validity; CU: Clinical Utility.

Pacific Edge Chairman Chris Gallaher said: “The inclusion of Cxbladder Triage in the AUA guideline has allowed the company to view the Medicare non-coverage determination that came into effect in April 2025 differently.

“The Company has a strong desire to use those guidelines to build on the commercial momentum already established. The robust evidence emerging from its clinical evidence program is shifting clinical sentiment towards the broader adoption of Pacific Edge’s tests in the US and further afield. Pacific Edge is determined not to lose that momentum, and it is for this reason it is undertaking the capital raising,” Mr Gallaher said.

Eligible Shareholders can apply for shares under the SPP online at www.pacifedge.capitalraise.co.nz or alternatively complete and return a hard copy Application Form (which is available on request from Pacific Edge’s Share Registrar, MUFG Pension & Market Services) before 7.00pm NZT on the Closing Date, which is Thursday 31 July 2025 (unless the SPP offer period is extended). Applications received after the Closing Date may not be accepted.

To request a hard copy Application Form, please contact Pacific Edge’s Share Registrar:

MUFG Pension & Market Services

Level 30, PwC Tower

15 Customs Street West

Auckland 1010

Telephone +64 9 375 5998

Email: enquiries.nz@cm.mpms.mufg.com

KEY DATES OF THE SPP*

DATE	EVENT	DESCRIPTION
7.00 pm on 11 July 2025	Record Date	The date on which Eligible Shareholders are determined.
17 July 2025	Opening Date	Offer opens.
7.00 pm on 31 July 2025	Closing Date	Offer closes. Applications and payment must be received by no later than 7.00 pm.
6 August 2025	Annual Shareholders’ Meeting	Shareholders’ meeting to, amongst other things, approve the Placement.
13 August 2025	Allotment Date and commencement of trading on NZX	Shares are allotted under the Placement and the Offer. Trading of the Shares is expected to commence on the NZX Main Board on the Allotment Date and on ASX on the business day following the Allotment Date.

13 August 2025

Holding Statements

Holding Statements are sent to
Applicants who are allotted Shares
under the Offer.

* Subject to the NZX and ASX Listing Rules and applicable laws, Pacific Edge reserves the right to alter any dates for the SPP.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW

Pacific Edge: www.pacificedgedx.com

Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.